Suneet Agarwal

List of Publications by Year
in descending order

38 papers	1,386 citations	430442 18 h-index	414034 32 g-index
39 all docs	39 docs citations	39 times ranked	2297 citing authors

#	Article	IF	Citations
1	Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature, 2010, 464, 292-296.	13.7	302
2	Poly(A)-specific ribonuclease (PARN) mediates 3â€²-end maturation of the telomerase RNA component. Nature Genetics, 2015, 47, 1482-1488.	9.4	149
3	CTC1 Mutations in a patient with dyskeratosis congenita. Pediatric Blood and Cancer, 2012, 59, 311-314.	0.8	115
4	Induced Pluripotent Stem Cells with a Mitochondrial DNA Deletion. Stem Cells, 2013, 31, 1287-1297.	1.4	92
5	Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Science Translational Medicine, 2017, 9, .	5.8	87
6	Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPRâ€“Cas9 genome editing. Nature Biomedical Engineering, 2017, 1, 878-888.	11.6	83
7	Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. Cell Stem Cell, 2020, 26, 896-909.e8.	5.2	57
8	Mitochondrial function in development and disease. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	48
9	Understanding the evolving phenotype of vascular complications in telomere biology disorders. Angiogenesis, 2019, 22, 95-102.	3.7	45
10	Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease. Journal of Clinical Investigation, 2016, 126, 3377-3382.	3.9	45
11	Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. European Respiratory Journal, 2017, 49, 1601640.	3.1	41
12	Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita. Hematology/Oncology Clinics of North America, 2018, 32, 669-685.	0.9	41
13	Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival. ERJ Open Research, 2020, 6, 00003-2020.	1.1	33
14	Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation. PLoS ONE, 2016, 11, e0162409.	1.1	30
15	Telomerase RNA processing: Implications for human health and disease. Stem Cells, 2020, 38, 1532-1543.	1.4	28
16	The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood, 2021, 138, 898-911.	0.6	27
17	Simultaneous sequencing of oxidized methylcytosines produced by TET/JBP dioxygenases in Coprinopsis cinerea. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5149-58.	3.3	25
18	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood, 2020, 136, 3070-3081.	0.6	25

#	Article	IF	Citations
19	Impaired Hydroxylation of 5-Methylcytosine In TET2 mutated Patients with Myeloid Malignancies. Blood, 2010, 116, 1-1.	0.6	24
20	Telomere dynamics in dyskeratosis congenita: the long and the short of iPS. Cell Research, 2011, 21, 1157-1160.	5.7	19
21	Retinal findings and a novel TINF2 mutation in Revesz syndrome: Clinical and molecular correlations with pediatric retinal vasculopathies. Ophthalmic Genetics, 2017, 38, 51-60.	0.5	17
22	Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders. Journal of Pediatrics, 2021, 230, 55-61.e4.	0.9	14
23	Telomerase RNA recruits RNA polymerase II to target gene promoters to enhance myelopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2015528118.	3.3	8
24	A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding. Blood, 2016, 128, 2089-2092.	0.6	7
25	AID for reprogramming. Cell Research, 2010, 20, 253-255.	5.7	6
26	Exudative Vitreoretinopathy in Dyskeratosis Congenita. Ophthalmology, 2017, 124, 1246.	2.5	5
27	Full Donor Myeloid Engraftment with Minimal Toxicity in Dyskeratosis Congenita Patients Undergoing Allogeneic Bone Marrow Transplantation without Radiation or Alkylating Agents. Blood, 2014, 124, 2941-2941.	0.6	4
28	Telomere Length and Telomerase Complex Mutations Predict Fatal Treatment Toxicity after Stem Cell Transplantation in Patients with Myelodysplastic Syndrome. Blood, 2018, 132, 796-796.	0.6	3
29	GATA2 Mutations In Pediatric Myelodysplastic Syndromes and Bone Marrow Failure. Blood, 2013, 122, 1520-1520.	0.6	3
30	Congenital Xâ€linked Neutropenia with Myelodysplasia and Somatic Tetraploidy due to a Germline Mutation in SEPT6. American Journal of Hematology, 2021, , .	2.0	1
31	Telomere Elongation in Dyskeratosis Congenita Induced Pluripotent Stem Cells.. Blood, 2009, 114, 497-497.	0.6	1
32	Mutations in the Poly(A)-Specific Ribonuclease (PARN) Impair Telomerase RNA 3' End Maturation in Dyskeratosis Congenita Patients. Blood, 2015, 126, 669-669.	0.6	1
33	A Young Adult with Aplastic Anemia and Gray Hair. Clinical Chemistry, 2013, 59, 47-50.	1.5	0
34	Hepatic vascular remodelling in a patient with dyskeratosis congenita. Histopathology, 2021, , .	1.6	0
35	Translational potential of patientâ€specific human pluripotent stem cells. FASEB Journal, 2010, 24, 64.1.	0.2	0
36	Derivation of Disease-Free Induced Pluripotent Stem Cells From Patients with Pearson Marrow Pancreas Syndrome. Blood, 2010, 116, 3-3.	0.6	0

#	Article	IF	Citations
37	Pearson Marrow Pancreas Syndrome In a Cohort Of Diamond Blackfan Anemia Patients. Blood, 2013, 122, 1226-1226.	0.6	0
38	Congenital X-Linked Myelodysplasia with Tetraploidy Is Associated with De Novo Germline C-Terminal Mutation of SEPT6, a Septin Filament Protein. Blood, 2018, 132, 644-644.	0.6	0